Natera said it is preparing to expand beyond its U.S. MRD footprint after accruing multiple regulatory wins across geographies. The company highlighted FDA approval for Signatera in muscle-invasive bladder cancer, inclusion in NCCN guidelines, and approval from Japan’s PMDA for colorectal cancer, alongside European IVD certification. Natera framed the Japan expansion as enabling earlier integration of MRD into colorectal clinical practice and pointed to upcoming data readouts, including the VEGA randomized de-escalation study expected in 2027. For precision oncology operators, the update reflects how MRD tests are moving from niche research use toward guideline-supported clinical decision-making—if reimbursement pathways stay on track.